HYAL3 As a Potential Novel Marker of BLCA Patient Prognosis

Overview

Journal BMC Genom Data

Publisher Biomed Central

Specialty Genetics

Date 2022 Aug 9

PMID 35945500

Authors

Jun-Peng Liu

Yu-Tong Fang

Yi-Fan Jiang

Hao Lin

Affiliations

Soon will be listed here.

Abstract

Background: It has been previously demonstrated that hyaluronan (HA) potentially regulates the initiation and propagation of bladder cancer (BLCA). HYAL3 encodes hyaluronidase and is a potential therapeutic target for BLCA. We aimed to explore the role that HYAL3 plays in BLCA pathogenesis.

Methods: HYAL3 expression in BLCA specimens was analyzed using The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) cohort as well as confirmed in cell lines and The Human Protein Atlas. Then, associations between HYAL3 expression and clinicopathological data were analyzed using survival curves and receiver-operating characteristic (ROC) curves. The functions of HYAL3 were further dissected using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and the protein-protein interaction network. Finally, we harnessed the Tumor IMmune Estimation Resource and Gene Expression Profiling Interactive Analysis to obtain correlations between HYAL3 expression, infiltrating immunocytes, and the corresponding immune marker sets.

Results: HYAL3 expression varied greatly between many types of cancers. In addition, a higher HYAL3 expression level predicted a poor overall survival (OS) in both TCGA-BLCA and GEO gene chips (P < 0.05). HYAL3 also exhibited an acceptable diagnostic ability for the pathological stage of BLCA (area under the receiver-operating characteristic curve = 0.769). Furthermore, HYAL3 acted as an independent prognostic factor in BLCA patients and correlated with the infiltration of various types of immunocytes, including B cells, CD8 T cells, cytotoxic cells, T follicular helper cells, and T helper (Th) 2 cells.

Conclusion: HYAL3 might serve as a potential biomarker for predicting poor OS in BLCA patients and correlated with immunocyte infiltration in BLCA.

Citing Articles

Blood-based HYAL2 methylation as a potential marker for the preclinical detection of coronary heart disease and stroke.

Bi L, Jin J, Fan Y, Liu Y, Xu H, Li M Clin Epigenetics. 2024; 16(1):130.

PMID: 39285429 PMC: 11406760. DOI: 10.1186/s13148-024-01742-7.

References

Hofbauer S, de Martino M, Lucca I, Haitel A, Susani M, Shariat S . A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urol Oncol. 2018; 36(12):531.e1-531.e8. DOI: 10.1016/j.urolonc.2018.09.006. View

Csoka A, Frost G, Stern R . The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001; 20(8):499-508. DOI: 10.1016/s0945-053x(01)00172-x. View

Wang Q, Ji J, Li H, He P, Song L, Zhao Y . [Preoperative Lymphocyte-to-monocyte Ratio Predicts Prognosis in Patients with Stage T1 Non-muscle Invasive Bladder Cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019; 41(5):622-629. DOI: 10.3881/j.issn.1000-503X.11227. View

Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L . CD19 tumor-infiltrating B-cells prime CD4 T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2018; 68(1):45-56. PMC: 11028136. DOI: 10.1007/s00262-018-2250-9. View

Dumas A, Pomella N, Rosser G, Guglielmi L, Vinel C, Millner T . Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. EMBO J. 2020; 39(15):e103790. PMC: 7396846. DOI: 10.15252/embj.2019103790. View

Kiyokawa J, Kawamura Y, Ghouse S, Acar S, Barcin E, Martinez-Quintanilla J . Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2020; 27(3):889-902. PMC: 7854507. DOI: 10.1158/1078-0432.CCR-20-2400. View

Schneider A, Chevalier M, Derre L . The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019; 16(10):613-630. DOI: 10.1038/s41585-019-0226-y. View

Peng Y, Wu Z, Lu H, Wei W, Xiong L, Yu C . Prognostic significance of tumor-infiltrating immune cells in muscle-invasive bladder cancer. Am J Transl Res. 2020; 12(10):6524-6536. PMC: 7653560. View

Kang D, Bittner B, Sugarman B, Zepeda M, Printz M . Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer. PLoS One. 2021; 16(7):e0254765. PMC: 8297837. DOI: 10.1371/journal.pone.0254765. View

10.

Alfano M, Canducci F, Nebuloni M, Clementi M, Montorsi F, Salonia A . The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol. 2015; 13(2):77-90. PMC: 7097604. DOI: 10.1038/nrurol.2015.292. View

11.

Lu P, Weaver V, Werb Z . The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196(4):395-406. PMC: 3283993. DOI: 10.1083/jcb.201102147. View

12.

Jin Z, Zhang G, Liu Y, He Y, Yang C, Du Y . The suppressive role of HYAL1 and HYAL2 in the metastasis of colorectal cancer. J Gastroenterol Hepatol. 2019; 34(10):1766-1776. DOI: 10.1111/jgh.14660. View

13.

Pettenati C, Ingersoll M . Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018; 15(10):615-625. DOI: 10.1038/s41585-018-0055-4. View

14.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

15.

Jagadish N, Rana R, Mishra D, Garg M, Selvi R, Suri A . Characterization of immune response in mice to plasmid DNA encoding human sperm associated antigen 9 (SPAG9). Vaccine. 2005; 24(17):3695-703. DOI: 10.1016/j.vaccine.2005.07.007. View

16.

Xu F, Guan Y, Xue L, Huang S, Gao K, Yang Z . The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma. BMC Cancer. 2020; 20(1):1207. PMC: 7720455. DOI: 10.1186/s12885-020-07702-7. View

17.

Csoka A, Scherer S, Stern R . Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics. 1999; 60(3):356-61. DOI: 10.1006/geno.1999.5876. View

18.

Chalasani V, Chin J, Izawa J . Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009; 3(6 Suppl 4):S193-8. PMC: 2792446. DOI: 10.5489/cuaj.1195. View

19.

Waardenberg A, Field M . consensusDE: an R package for assessing consensus of multiple RNA-seq algorithms with RUV correction. PeerJ. 2019; 7:e8206. PMC: 6913255. DOI: 10.7717/peerj.8206. View

20.

Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H . Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2018; 24(13):3069-3078. DOI: 10.1158/1078-0432.CCR-17-2687. View